FDA
- Status: approved
🇺🇸 Milrinone infusion in United States
12 US adverse-event reports
Marketing authorisation
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 20 April 2025 – 20 April 2026
- Total reports: 12
Most-reported reactions
- Hypotension — 4 reports (33.33%)
- Cardiac Arrest — 3 reports (25%)
- Developmental Delay — 1 report (8.33%)
- Dyspnoea — 1 report (8.33%)
- Hepatomegaly — 1 report (8.33%)
- Microcytic Anaemia — 1 report (8.33%)
- Seizure — 1 report (8.33%)
Milrinone infusion in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Milrinone infusion approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Milrinone infusion in United States?
NICHD Neonatal Research Network is the originator. The local marketing authorisation holder may differ — check the official source linked above.